Lonza expands development and manufacturing capabilities at Bend site
The company will invest in dedicated early-phase development and cGMP manufacturing to help customers rapidly advance challenging molecules
Lonza is expanding its development and manufacturing capabilities at its Bend (OH) site, spurred by increased demand for development, clinical and commercial manufacture of particle-engineered intermediates and finished drug products, the CDMO said Monday.
The company's "significant" investment will establish a total of 11 new suites for the development and clinical manufacture of drug product intermediates and drug products utilizing spray-drying, hot-melt extrusion and melt-spray-congeal processing, which will be completed by May 2022.
The first suite will expand early-phase spray-drying, tabletting and encapsulation capability, and is expected to be on-line by December 2020.
As part of the investment, the new current Good Manufacturing Practice (cGMP) suites will be added to support early-phase manufacture incorporating additional storage, gowning, and a customer in-plant viewing corridor.
Non-cGMP capability for formulation and process development will also be expanded with one new suite.
The investment increases both capacity and flexibility across particle engineering and oral drug products, including immediate-release tablets, multiparticulates, and dry powder encapsulation for oral solid and inhaled applications.
“Our customers look to Lonza to rapidly advance challenging molecules and meet increasingly difficult target product profiles. We listened, and this new investment is aimed directly at meeting those needs,” said Christian Dowdeswell, Vice President and Global Head of Commercial Development for Small Molecules business, Lonza.
Lonza Bend is the Center of Excellence for bioavailability enhancement and inhaled delivery for the company's Small Molecules business unit.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance